Insight Molecular Diagnostics (IMDX) vs Lantheus (LNTH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Lantheus (LNTH) has outperformed Insight Molecular Diagnostics (IMDX) over the past year, gaining 93.2% versus a loss of 6.0%. Over five years, LNTH leads with a +330.7% price change compared with -94.9% for IMDX. Lantheus is the larger company by market cap ($6.54 billion vs $113.2 million), about 57.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMDX | LNTH |
|---|---|---|
| Share price | $3.46 | $100.18 |
| Market cap | $113.23M | $6.54B |
| 1-day change | +2.37% | +0.23% |
| YTD return | -53.87% | +50.53% |
| 1-year return | -5.98% | +93.25% |
| 5-year return | -94.91% | +330.70% |
| P/E ratio (TTM) | — | 24.26 |
| Forward P/E | — | 15.71 |
| EPS (TTM) | $-1.52 | $4.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.54B |
| Revenue growth (YoY) | — | +0.50% |
| Net income (latest FY) | — | $233.56M |
| Gross margin | — | 61.10% |
| Operating margin | — | 20.16% |
| Net margin | — | 15.15% |
| 52-week high | $8.51 | $111.86 |
| 52-week low | $2.42 | $50.16 |
| Distance from 52-week high | -59.34% | -10.44% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +7.55% |
| Average volume | 233.13K | 1.32M |
| Shares outstanding | 32.72M | 65.30M |
| Employees | — | 1,193 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Lantheus is about 57.8 times larger than Insight Molecular Diagnostics by market value ($6.54B vs $113.23M).
- LNTH has outperformed IMDX by 99.2 percentage points over the past year.
About Lantheus
LNTH stock →Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 1,193 employees
IMDX vs LNTH FAQ
Which is bigger, Insight Molecular Diagnostics or Lantheus?
Lantheus (LNTH) is larger, with a market capitalization of $6.54B compared with $113.23M for Insight Molecular Diagnostics (IMDX).
Which stock has performed better over the past year, IMDX or LNTH?
LNTH returned +93.25% over the past 12 months, compared with -5.98% for IMDX (price return, excluding dividends). Past performance does not predict future results.
Are Insight Molecular Diagnostics and Lantheus in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.